Aug 28 (Reuters) - The U.S. Food and Drug Administration
said on Thursday it is recommending an additional, earlier
magnetic resonance imaging monitoring prior to the third
infusion for patients with Alzheimer's disease taking Biogen's
drug Leqembi.